RGT 264
Alternative Names: RGT-264Latest Information Update: 19 Dec 2024
At a glance
- Originator Regor Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 23 Oct 2024 Pharmacodynamics, immunogenicity data from preclinical trials in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 23 Oct 2024 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 15 Feb 2023 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater) in China (PO) (NCT05764915)